The development of therapeutic antibodies is a long process and comes with many pitfalls. The use of high-quality and structurally defined recombinant proteins for screening and quality control can reduce the level of uncertainty throughout the research and development process.
This is especially critical for bispecific antibodies, which are regarded as the second generation of antibody cancer therapies.
- Bispecific antibodies mechanisms of action
- Quality control of CD3-targeting bispecific antibodies
- Verifying recombinant CD3 heterodimers for quality control
